The Future of Influenza Vaccines

11:00 AM - 12:00 PM, Wednesday, June 5,2019 ・ 115C, Level 100
This session will discuss the spectrum of technologies, both short and long term, that would help drive expedient and broader development for seasonal and pandemic flu vaccines. Panel members will consider ways to improve egg-based vaccines, leverage cell based and recombinant platforms, apply new technology, and develop vaccines with heterologous protection as we move towards a universal approach. This session would be a combination of succinct presentations on the science and process evolution among the differing innovations. Participants will discuss the opportunities and challenges of regulatory processes, real world evidence, investment costs and data that informs market uptake to help stakeholders and industry fulfill the global health community goals for influenza prevention
Speakers
photo
President
Seqirus
photo
Director of the Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration
photo
President and Chief Executive Officer
FluGen Inc.
photo
Vice President, Technical Staff
In-Q-Tel
photo
Senior Vice President, Chief Business Officer and Chief Financial Officer
Novavax, Inc.